Acupuncture in Multiple Myeloma Peripheral Neuropathy: A Systematic Review
DOI: https://doi.org/10.2147/jpr.s448634
IF: 2.8319
2024-04-25
Journal of Pain Research
Abstract:Chunyi Lyu, 1 Hongyan Xiao, 1 Xuewei Yin, 2 Zonghong Li, 1 Chen Han, 1 Ruirong Xu 3, 4 1 First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China; 2 Affiliated Eye Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250002, People's Republic of China; 3 Key Laboratory of Integrated Traditional Chinese and Western Medicine for Hematology, Health Commission of Shandong Province; Institute of Hematology, Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China; 4 Department of Hematology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, People's Republic of China Correspondence: Ruirong Xu, Email Background: Peripheral neuropathy (PN) is a prevalent complication of multiple myeloma (MM), due to the disease itself or its treatment. Despite extensive research, the optimal treatment for multiple myeloma peripheral neuropathy (MMPN) remains unclear. Clinical practice has shown the potential efficacy of acupuncture in managing MMPN. This study aimed to conduct a comprehensive analysis of the literature to assess the effectiveness and safety of acupuncture as a treatment for MMPN. Methods: The PubMed, Web of Science, MEDLINE, Cochrane Library, and Embase databases were comprehensively searched from inception to November 1, 2023 to identify relevant studies pertaining to the use of acupuncture to treat MMPN. Results: A total of five studies, encompassing 97 patients diagnosed with drug-related PN, were ultimately included in this analysis. The literature lacks any reports pertaining to the utilization of acupuncture for disease-related PN. ST36, LI4, SP6, and EX-LE-10 were found to be the most frequently chosen acupoints. Following acupuncture treatment, there was a consistent reduction in scores on the Visual Analogue Scale (VAS), Neuropathic Pain Scale (NPS), Brief Pain Inventory-Short Form (BPI-SF), and Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) among MMPN patients. The results of Nerve Conduction Velocity (NCV) tests yielded conflicting results. No severe adverse effects were reported. Conclusion: The use of acupuncture for disease-related PN has not been studied to date. Acupuncture is safe for drug-related PN and is helpful for relieving pain. But uncertainty exists regarding the efficacy of this approach because there is substantial heterogeneity with respect to acupuncture treatment regimens, and more high-quality studies on this topic are warranted. Keywords: multiple myeloma peripheral neuropathy, acupuncture, pain, systematic review Multiple myeloma (MM) is a neoplastic disorder characterized by the proliferation of plasma cells within the bone marrow. 1 Peripheral neuropathy (PN) is a common complication of MM that mainly manifests as sensory neuropathies and motor neuropathies in severe cases. 2 Multiple myeloma peripheral neuropathy (MMPN) can be divided into disease-related PN and drug-related PN. In disease-related PN, sensory modalities may be affected, resulting in axonal sensorimotor neuropathy with a length-dependent pattern of axonal regrowth. 3 Drug-related PN is mainly caused by first-line drugs such as the proteasome inhibitor bortezomib and the immunomodulator thalidomide, which is one of the major challenges in the current drug management of MM. 4 Clinical evaluations suggest that up to 20% of patients with MM develop PN at diagnosis, and up to 75% of patients may develop therapeutic PN during treatment. 5 Among drug-related PNs, the incidence of bortezomib-induced peripheral neuropathy (BIPN) can reach 40%, and the incidence of thalidomide-induced peripheral neuropathy (TIPN) varies greatly, ranging from 25% to 75%. 6 MMPN has a significant impact on patients' physical and mental health and quality of life. The occurrence and severity of drug-related PN are strongly related to the drug dose. 7 Severe drug-related PN can only control the development of neurotoxicity by adjusting the dose, changing the route of administration, interrupting drugs or prolonging the interval between chemotherapy, which also reduces the therapeutic effect of the primary disease. Available treatment options for the prevention and treatment of MMPN are limited. Generally, vitamin B drugs are administered to nourish nerves, and painkillers are used to relieve pain, but the effect is not satisfactory. Therefore, an effective treatment method is urgently needed to control the occurrence and development of MMPN. A large amount of medical -Abstract Truncated-
clinical neurology